10-Q: Skinvisible Inc. Reports Second Quarter 2024 Results Amidst Going Concern Uncertainty

Skinvisible Inc. reports a net loss of $593,821 for the six months ended June 30, 2024, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Skinvisible Inc. reported a net loss of $303,449 for the three months ended June 30, 2024, and a net loss of $593,821 for the six months ended June 30, 2024.
• The company's revenue remained consistent at $5,000 for the three-month periods ending June 30, 2024 and 2023, and $10,000 for the six-month periods ending June 30, 2024 and 2023.
• Operating expenses increased to $147,693 for the three months ended June 30, 2024, and $275,877 for the six months ended June 30, 2024.
• The company's total assets were $163,058 as of June 30, 2024, with total current liabilities of $4,023,571, resulting in a working capital deficit of $3,987,689.
• Skinvisible has incurred cumulative net losses of $39,974,309 since its inception and requires capital for its operational and marketing activities.
• The company's ability to continue as a going concern is uncertain, dependent on securing additional financing through licensing, debt, or equity funding.
• The company is actively pursuing strategic partnerships to commercialize its transdermal delivery technology for obesity and glucose-controlling agents.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a substantial working capital deficit, and a going concern warning, which overshadows any positive developments. The company's reliance on future financing and licensing revenue creates a high level of uncertainty.

Positives

• Skinvisible is actively pursuing strategic partnerships to commercialize its transdermal delivery technology.
• The company has filed provisional patent applications for transdermal delivery of obesity and glucose-controlling agents, potentially opening new revenue streams.
• Quoin's clinical trials for product formulations containing Invisicare targeting Netherton Syndrome have shown positive initial data and a clean safety profile.
• Quoin received FDA clearance to recruit teen subjects into its Netherton Syndrome clinical studies, potentially expediting recruitment and leading to a more robust data set.

Negatives

• Skinvisible has incurred significant cumulative net losses of $39,974,309 since its inception.
• The company's revenue has remained flat at $5,000 for the three-month periods and $10,000 for the six-month periods.
• Operating expenses have increased, contributing to the net loss.
• The company has a substantial working capital deficit of $3,987,689.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to its financial condition.
• Skinvisible faces risks related to obtaining adequate financing on a timely basis and on acceptable terms.
• There are risks related to the company's operations and uncertainties related to its business plan and strategy.
• The company faces uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement.
• The company's disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• The company's remediation efforts are dependent on securing additional financing.

Future Outlook

The company intends to fund operations through increased sales and debt and/or equity financing arrangements, and plans to seek additional financing in a private equity offering. They also plan to enter into commercial arrangements with pharma and biotech companies to exploit their recently filed patent applications.

Management Comments

• Management believes the company is not exposed to significant interest or credit risks arising from these financial instruments.
• Management's plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding.
• Management has identified material weaknesses in internal control over financial reporting and plans to implement changes to address these weaknesses.

Industry Context

The company operates in the pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas, targeting an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market. The company's business model is to out-license its patented products to established manufacturers and marketers, which is a common strategy for smaller R&D companies in the pharmaceutical industry.

Comparison to Industry Standards

• Skinvisible's revenue of $10,000 for the first six months of 2024 is significantly lower than many comparable pharmaceutical and biotech companies, especially those with marketed products.
• The company's net loss of $593,821 for the first six months of 2024 is also substantial, indicating a lack of profitability, which is not uncommon for early-stage R&D companies but is a concern given the company's history.
• The company's reliance on licensing revenue is similar to other biotech companies that focus on R&D, but the lack of significant revenue generation is a major concern.
• The company's working capital deficit of $3,987,689 is a significant challenge, as many companies in the sector have positive working capital or access to capital markets.
• Compared to companies like Quoin Pharmaceuticals, which is actively conducting clinical trials, Skinvisible is more reliant on its partners' success for revenue generation.
• The company's focus on transdermal delivery is a growing area in the pharmaceutical industry, but the company is still in the early stages of commercialization.

Corporate Governance

Related Party Transactions

• During the three months ended June 30, 2024 and 2023, the Company repaid net $1,800 and $0 in advances due to related parties.
• As of June 30, 2024 and December 31, 2023, the Company had amounts due from related parties of $4,200 and $6,000, respectively.
• On January 31, 2023, the Company renegotiated accrued salaries, vacation, and outstanding convertible notes for its two officers, converting them to promissory notes convertible into common stock with a warrant feature.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be concerned about the company's ability to continue operations and maintain employment.
• Customers and partners may be hesitant to engage with the company due to its financial challenges.
• Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to seek additional financing in a private equity offering.
• The company intends to pursue strategic partnerships to commercialize its transdermal delivery technology.
• The company plans to implement changes to address material weaknesses in internal control over financial reporting.
• The company hopes to generate more revenues from its licenses with Quoin and Ovation for the rest of 2024.
• The company plans to enter into commercial arrangements with pharma and biotech companies to exploit its patent applications that were recently filed.

Key Dates

Keywords

Invisicare, transdermal delivery, obesity, glucose-controlling agents, licensing, pharmaceutical, dermatology, patents, clinical trials, Netherton Syndrome, financial results, going concern